GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Earnings per Share (Diluted)

XORTX Therapeutics (TSXV:XRTX) Earnings per Share (Diluted) : C$-0.03 (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Earnings per Share (Diluted)?

XORTX Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was C$-0.27. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.03.

XORTX Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was C$-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.03.

XORTX Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was C$-0.39. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was C$-1.17.

During the past 3 years, the average EPS without NRIGrowth Rate was -30.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -36.70% per year.

During the past 9 years, XORTX Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 21.40% per year. The lowest was -107.70% per year. And the median was -26.35% per year.


XORTX Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for XORTX Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Earnings per Share (Diluted) Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only -1.09 -1.72 -1.84 -7.09 -1.46

XORTX Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 1.84 -1.68 0.08 -0.27

Competitive Comparison of XORTX Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, XORTX Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's PE Ratio falls into.



XORTX Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

XORTX Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.895-0)/1.982
=-1.46

XORTX Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.795-0)/2.904
=-0.27

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


XORTX Therapeutics  (TSXV:XRTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


XORTX Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Executives
Allen Warren Davidoff Director, Senior Officer
Amar Deep Keshri Senior Officer
William Bruce Rowlands Director
James Neville Fairbairn Senior Officer
Allan William Williams Director
Paul Joseph Van Damme Director